{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:55:23Z","timestamp":1793480123683,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1704185"],"award-info":[{"award-number":["U1704185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["232300421182"],"award-info":[{"award-number":["232300421182"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejmech.2025.117656","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T18:53:26Z","timestamp":1745002406000},"page":"117656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Design, synthesis and biological activity of novel pyrimidine piperazine ureas as \u03bc-opioid and TRPV1 dual-target ligands for pain management"],"prefix":"10.1016","volume":"292","author":[{"given":"Yusui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117656_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.spen.2016.10.003","article-title":"Pathogenesis of pain","volume":"23","author":"Dinakar","year":"2016","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.ejmech.2025.117656_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00002018-200629020-00002","article-title":"NSAID-Associated adverse effects and acid control aids to prevent them","volume":"29","author":"N\u00e6sdall","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2025.117656_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejpain.2004.05.004","article-title":"Opioids in neuropathic pain: clues from animal studies","volume":"9","author":"Dickenson","year":"2005","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejmech.2025.117656_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib5","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology-foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib6","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel approaches, drug candidates, and targets in pain drug discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib7","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.4155\/fmc.15.156","article-title":"The design of multitarget ligands for chronic and neuropathic pain","volume":"7","author":"Dvoracsko","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/cbdd.12479","article-title":"Design, synthesis and biological evaluation of two opioid agonist and Cav 2.2 blocker multitarget ligands","volume":"86","author":"Mollica","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.117656_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/med.21427","article-title":"Medicinal chemistry, pharmacology, and clinical implications of TRPV1 receptor antagonists","volume":"37","author":"Tabrizi","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117656_bib10","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/bph.14044","article-title":"Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field","volume":"175","author":"Moran","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117656_bib11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.neuron.2012.12.016","article-title":"TRPV1 channels are intrinsically heat sensitive and negatively regulated by phosphoinositide lipids","volume":"77","author":"Cao","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2025.117656_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543776.2021.1854225","article-title":"A patent review of transient receptor potential vanilloid type 1 modulators (2014-present)","volume":"31","author":"Gao","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117656_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/13543776.2015.1008449","article-title":"Transient receptor potential vanilloid type 1 antagonists: a patent review (2011-2014)","volume":"25","author":"Lee","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117656_bib14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1523\/JNEUROSCI.5150-09.2010","article-title":"Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia","volume":"30","author":"Garami","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117656_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1124\/jpet.111.190314","article-title":"Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature","volume":"342","author":"Reilly","year":"2012","journal-title":"The J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2025.117656_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107474","article-title":"Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis","volume":"208","author":"Garami","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117656_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172934","article-title":"In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523","volume":"871","author":"Damann","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117656_bib18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/pr.112.007138","article-title":"Mu opioids and their receptors: evolution of a concept","volume":"65","author":"Pasternak","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2025.117656_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic potential of \u03b2-arrestin- and G protein-biased agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117656_bib20","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking \u03b2-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science (N. Y.)"},{"key":"10.1016\/j.ejmech.2025.117656_bib21","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(19)30430-1","article-title":"Perioperative opioid Analgesia\u2014When is enough too much? A review of opioid-induced tolerance and hyperalgesia","volume":"393","author":"Colvin","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117656_bib22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"\u03bc-Opioid receptor desensitization by \u03b2-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117656_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/19336950.2015.1069450","article-title":"The mechanism of \u03bc-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence","volume":"9","author":"Bao","year":"2015","journal-title":"Channels"},{"key":"10.1016\/j.ejmech.2025.117656_bib24","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.3390\/ijerph19042387","article-title":"Side effects of opioids are ameliorated by regulating TRPV1 receptors","volume":"19","author":"Wang","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.ejmech.2025.117656_bib25","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1523\/JNEUROSCI.4170-07.2008","article-title":"Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway","volume":"28","author":"Chen","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117656_bib26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bja\/aeq212","article-title":"Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in mice","volume":"105","author":"Nguyen","year":"2010","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejmech.2025.117656_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jpain.2008.07.004","article-title":"TRPV1 receptor in expression of opioid-induced hyperalgesia","volume":"10","author":"Vardanyan","year":"2009","journal-title":"J. Pain"},{"key":"10.1016\/j.ejmech.2025.117656_bib28","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib29","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112236","article-title":"Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide","volume":"194","author":"Nie","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114191","article-title":"Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl) pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist","volume":"233","author":"Qiao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106335","article-title":"Novel dual-target \u03bc-opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management","volume":"131","author":"Gao","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116208","article-title":"Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management","volume":"267","author":"Qiao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/128_2010_76","article-title":"Twin and triplet drugs in opioid research","volume":"299","author":"Fujii","year":"2011","journal-title":"Chem. Opioids"},{"key":"10.1016\/j.ejmech.2025.117656_bib35","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1021\/jm300780p","article-title":"2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region","volume":"55","author":"Kim","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpain.2010.07.006","article-title":"Combination drug therapy for chronic pain: a call for more clinical studies","volume":"12","author":"Mao","year":"2011","journal-title":"J. Pain"},{"key":"10.1016\/j.ejmech.2025.117656_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111634","article-title":"Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain","volume":"182","author":"Lee","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117656_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1476-5381.1980.tb10422.x","article-title":"Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with \u03bc- and \u03b4-receptors","volume":"68","author":"Kosterlitz","year":"1980","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117656_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"Fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejmech.2025.117656_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0304-3959(87)90088-1","article-title":"The formalin test in mice: dissociation between inflammatory and non-inflammatory pain","volume":"30","author":"Hunskaar","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2025.117656_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0304-3959(89)90222-4","article-title":"Modified formalin test: characteristic biphasic pain response","volume":"38","author":"Shibata","year":"1989","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2025.117656_bib42","doi-asserted-by":"crossref","first-page":"15709","DOI":"10.1021\/acs.jmedchem.0c01367","article-title":"Synthesis and biological characterization of cyclic disulfide-containing peptide analogs of the multifunctional opioid\/neuropeptide FF receptor agonists that produce long-lasting and nontolerant antinociception","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:09:42Z","timestamp":1762265382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"alternative-id":["S0223523425004210"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117656","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological activity of novel pyrimidine piperazine ureas as \u03bc-opioid and TRPV1 dual-target ligands for pain management","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117656"}}